Pharvaris BV (PHVS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.36B
Last updated: Nov 17, 2026 at 4:15 PM ET
Pharvaris BV (PHVS) Statistics
Pharvaris BV (PHVS) has a market cap of $2.36B. Its share count is up 12.96% from a year earlier.
Total Valuation
| Market Cap | $2.36B |
|---|---|
| Latest price (Nov 17, 2026) | $32.28 |
Key Dates
The next earnings report is expected on Apr 5, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Apr 5, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 37.07% over 52 weeks and trades 2.39% below its 50-day average.
| Beta (1Y) | 0.81 |
|---|---|
| 52-Week Change | +37.07% |
| 1-Month Change | +8.43% |
| 3-Month Change | -11.00% |
| 6-Month Change | +11.50% |
| 5-Year Change | +92.37% |
| Total Return (1Y) | +37.07% |
| Total Return (3Y CAGR) | +25.96% |
| Total Return (5Y CAGR) | +17.31% |
| Return vs SPY (1Y) | +23.11% |
| Max Drawdown (1Y) | -28.62% |
| Max Drawdown (3Y) | -63.11% |
| Sharpe Ratio (1Y) | 0.58 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $33.07 |
| 200-Day Average | $31.39 |
| 52-Week Range | $23.15 to $43.25 |
| RSI (14 Days) | 45.9 |
| Average Volume (20 Days) | 522.70K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 9.89x current liabilities.
| Current Ratio | 9.89x |
|---|---|
| Quick Ratio | 9.89x |
Returns and Efficiency
Return on equity is -69.72% over the last 12 months, against a 5-year average of -42.63%.
| Return on Equity (ROE) | -69.72% |
|---|---|
| Return on Assets (ROA) | -62.61% |
| ROE (5Y Average) | -42.63% |
| ROA (5Y Average) | -39.06% |
| ROIC (5Y Average) | -44.61% |
Scores
PHVS has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was EUR 0 over the last 12 months.
| Revenue | EUR 0 |
|---|---|
| Operating Income | EUR -193.47M |
| Pretax Income | EUR -179.08M |
| Net Income | EUR -181.84M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 89.80% of the EUR 295.06M in total assets.
| Working Capital | EUR 263.55M |
|---|---|
| Shareholder Equity | EUR 264.97M |
| Total Assets | EUR 295.06M |
| Total Liabilities | EUR 30.09M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After EUR 81.40K of capital spending, operating cash flow left EUR -167.62M of free cash flow.
| Operating Cash Flow | EUR -167.54M |
|---|---|
| Capital Expenditures | EUR 81.40K |
| Free Cash Flow | EUR -167.62M |
| Depreciation and Amortization | EUR 483.00K |
Trailing 12 months through Sep 30, 2026.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PHVS
What is PHVS's market cap?
Pharvaris BV has a market cap of $2.36B.
How many shares of PHVS are outstanding?
Pharvaris BV has 70.33M shares outstanding. The count is up 12.96% from a year earlier.
Does PHVS pay a dividend?
No. Pharvaris BV does not pay a dividend.
PHVS pages: Overview, Charting, Financials, Statistics, Competitors